Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312139165> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4312139165 abstract "<h3>Objectives</h3> Primary Objective: To evaluate the efficacy in terms of the probability of surviving progression free for at least 6 months (PFS at 6 mo). Secondary Objective: To determine the proportion responding by RECIST v1.1 in patients with advanced, persistent, or recurrent endometrioid endometrial cancer. To estimate the time to disease progression or death (PFS and OS endpoints). To describe the toxicities in patients receiving combination therapy with letrozole and abemaciclib with advanced/metastatic endometrial cancer. <h3>Methods</h3> Key Eligibility Criteria:-Advanced (FIGO 2014 Stage III or IV), persistent, or recurrent endometrial carcinoma -Must have endometrioid histology (all grades allowed) (Hormone receptor status is not required for enrollment). -Must have measurable disease by RECIST v1.1. -Prior chemotherapy in the adjuvant setting for Stage I, II, or III is permitted. -Prior chemoradiotherapy for a pelvic recurrence is permitted. -Prior immunotherapy and/or targeted therapy is allowed in addition to, in combination with, in lieu of, or subsequent to prior chemotherapy. Regardless of circumstances, no more than one prior chemotherapy regimen (including chemo-radiotherapy) is permitted, and no more than one additional systemic therapy is permitted. Hence, eligible patient may have received 0, 1, or 2 prior lines of systemic therapy and for women who received two prior lines of therapy, only one of them may have included chemotherapy. -ECOG performance status of 0–1. -Must be able to swallow oral medications. <h3>Results</h3> Trial in progress: there are no available results at the time of submission. <h3>Conclusions</h3> Trial in progress: there are no available conclusions at the time of submission." @default.
- W4312139165 created "2023-01-04" @default.
- W4312139165 creator A5009234043 @default.
- W4312139165 creator A5022379846 @default.
- W4312139165 creator A5032022793 @default.
- W4312139165 creator A5043064148 @default.
- W4312139165 creator A5062471254 @default.
- W4312139165 creator A5062645957 @default.
- W4312139165 creator A5072447565 @default.
- W4312139165 creator A5086395173 @default.
- W4312139165 date "2022-12-01" @default.
- W4312139165 modified "2023-09-27" @default.
- W4312139165 title "TP011/#1527 GOG 3039 a phase II study of abemaciclib in combination with letrozole in advanced, recurrent or metastatic endometrioid endometrial cancer" @default.
- W4312139165 doi "https://doi.org/10.1136/ijgc-2022-igcs.520" @default.
- W4312139165 hasPublicationYear "2022" @default.
- W4312139165 type Work @default.
- W4312139165 citedByCount "0" @default.
- W4312139165 crossrefType "proceedings-article" @default.
- W4312139165 hasAuthorship W4312139165A5009234043 @default.
- W4312139165 hasAuthorship W4312139165A5022379846 @default.
- W4312139165 hasAuthorship W4312139165A5032022793 @default.
- W4312139165 hasAuthorship W4312139165A5043064148 @default.
- W4312139165 hasAuthorship W4312139165A5062471254 @default.
- W4312139165 hasAuthorship W4312139165A5062645957 @default.
- W4312139165 hasAuthorship W4312139165A5072447565 @default.
- W4312139165 hasAuthorship W4312139165A5086395173 @default.
- W4312139165 hasBestOaLocation W43121391651 @default.
- W4312139165 hasConcept C121608353 @default.
- W4312139165 hasConcept C126322002 @default.
- W4312139165 hasConcept C143998085 @default.
- W4312139165 hasConcept C2776694085 @default.
- W4312139165 hasConcept C2776907518 @default.
- W4312139165 hasConcept C2776999253 @default.
- W4312139165 hasConcept C2777088508 @default.
- W4312139165 hasConcept C2781413609 @default.
- W4312139165 hasConcept C509974204 @default.
- W4312139165 hasConcept C71924100 @default.
- W4312139165 hasConceptScore W4312139165C121608353 @default.
- W4312139165 hasConceptScore W4312139165C126322002 @default.
- W4312139165 hasConceptScore W4312139165C143998085 @default.
- W4312139165 hasConceptScore W4312139165C2776694085 @default.
- W4312139165 hasConceptScore W4312139165C2776907518 @default.
- W4312139165 hasConceptScore W4312139165C2776999253 @default.
- W4312139165 hasConceptScore W4312139165C2777088508 @default.
- W4312139165 hasConceptScore W4312139165C2781413609 @default.
- W4312139165 hasConceptScore W4312139165C509974204 @default.
- W4312139165 hasConceptScore W4312139165C71924100 @default.
- W4312139165 hasLocation W43121391651 @default.
- W4312139165 hasOpenAccess W4312139165 @default.
- W4312139165 hasPrimaryLocation W43121391651 @default.
- W4312139165 hasRelatedWork W200989379 @default.
- W4312139165 hasRelatedWork W2234839489 @default.
- W4312139165 hasRelatedWork W2348873804 @default.
- W4312139165 hasRelatedWork W2387456186 @default.
- W4312139165 hasRelatedWork W2387577256 @default.
- W4312139165 hasRelatedWork W2388730008 @default.
- W4312139165 hasRelatedWork W2407189953 @default.
- W4312139165 hasRelatedWork W3138778581 @default.
- W4312139165 hasRelatedWork W4312139165 @default.
- W4312139165 hasRelatedWork W757206253 @default.
- W4312139165 isParatext "false" @default.
- W4312139165 isRetracted "false" @default.
- W4312139165 workType "article" @default.